208 results about "Viral disease" patented technology

The invention discloses a bovine I-type alpha interferon-ferritin fusion protein, a mutant thereof, a preparation method and an application of the bovine I-type alpha interferon-ferritin fusion protein. The bovine I-type alpha interferon is fused with a ferritin subunit, and interferon molecules are highly repeatedly and orderly displayed on the surface of a ferritin nanocage by utilizing the self-assembly characteristic of ferritin, so that the expression level, the structural stability and the antiviral activity of the interferon are remarkably improved. The fusion protein is further subjected to single-site or multi-site rational design mutation, and a mutant with significantly improved antiviral activity and stability is obtained. According to the invention, a silkworm or insect cell eukaryotic expression system is adopted to express the fusion protein or the mutant thereof, and the expression system is safe to operate, simple and convenient in procedure, low in cost and extremely beneficial to large-scale industrial production; the prepared fusion protein or mutant nanoparticles have application prospects in preparation of drugs or reagents for preventing or treating bovine viral diseases.

Provided are methods and compounds for treating (or for use in manufacturing a pharmaceutical dosage form to treat) viral infections by administering avermectin-based bioavailable highly permeable compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of SARS-CoV-2, dengue, chikungunya, yellow fever, Zika and other viral infections.

The invention discloses a grass carp gamma interferon fusion protein as well as a mutant, a coding gene and application thereof. In order to improve the expression quantity or expression efficiency of the grass carp gamma interferon, codon optimization and mutation are carried out on the coding gene of the grass carp gamma interferon to obtain the grass carp gamma interferon mutant. The fusion protein is further obtained by connecting the grass carp gamma interferon mutant with the C end of the grass carp ferritin heavy chain subunit of which the last 17 amino acids are removed through a connecting peptide. In order to further improve the antiviral activity of the fusion protein, the obtained fusion protein is subjected to single-point mutation, and the titer of the fusion protein is remarkably improved. The fusion protein is expressed by a silkworm cell eukaryotic expression system, and the fusion protein shows a conformation suitable for the interferon to play functions based on the ferritin self-assembly characteristic, so that the titer of the interferon in a host is effectively improved, and the in-vivo and in-vitro half-life period of the interferon is prolonged. The invention has application prospects in preparation of drugs or reagents for preventing or treating viral diseases of grass carp and the like.

The present invention belongs to the technical field of biological prevention and treatment for viral diseases. Disclosed in the present invention are a tomato disease-resistant gene mutant, and the use thereof in the prevention and treatment of ToBRFV. It is found in the present invention that mutating the nucleotide at position 1927 of the coding region sequence of tomato Tm-22 gene from G to A, or mutating the amino acid at position 643 of the LRR domain of a protein that is encoded by tomato Tm-22 gene from glycine to arginine can remarkably reduce the accumulation level of ToBRFV capsid protein (CP). The gene (named Tm-22-Mut5) can serve as a novel ToBRFV resistant gene, and also retains the resistance to TMV, ToMV and ToMMV. The Tm-22-Mut5 and a pre-screened Tm-22-Mut3-1 mutant (tyrosine at position 767 of the LRR domain thereof is mutated to phenylalanine) undergo combinatorial mutagenesis to obtain a mutant Tm-22-Mut6. Analysis shows that the Tm-22-Mut6 can remarkably reduce the accumulation level of the ToBRFV capsid protein. Compared with the pFGCTm-22-Mut3-1 mutant obtained by screening in the previous research and the newly obtained mutant Tm-22-Mut5, the Tm-22-Mut6 has further improved resistance to ToBRFV.

The invention discloses a special growth regulator for pepper based on compounding of propionyl brassinolide and amino-oligosaccharin and application of the special growth regulator, and belongs to the technical field of agricultural biology. According to the regulating agent, 0.0008 to 0.0012 percent of propionyl brassinolide and 2.95 to 3.05 percent of amino-oligosaccharin are accurately matched with each other. The formula breaks through the contradiction between the root promotion requirement of high-dose amino-oligosaccharin and the safety threshold of low-dose brassinolide, and overcomes the phytotoxicity risk of the traditional dosage form. The regulator prepared by the invention can enhance the growth vigor of the pepper, improve the product and quality of the pepper, and also can effectively prevent viral diseases of the pepper.

The invention belongs to the technical field of plant cultivation, and relates to a cultivation method for preventing and controlling plant viral diseases. The invention provides a cultivation method for preventing and controlling plant viral diseases. The cultivation method comprises the following steps: doping a soil microorganism conditioning additive when furrowing and applying a base fertilizer in a field, and doping the soil microorganism conditioning additive when dressing a fertilizer, the soil microorganism conditioning additive is composed of sodium alginate, a crushed material of an underground part of Khaxican eggplant and a crushed material of an underground part of rubus alceolatus. The cultivation method provided by the invention can effectively solve the technical problem that viral diseases of various plants are difficult to control, and the yield of crops such as tobaccos, tomatoes and peppers is increased.

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1 / PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

The present invention relates to a pharmaceutical composition in inhalable pre-metered dry powder form that comprises at least one excipient (for example carrier) and at least one active substance used against viral diseases to locally administer it to the lungs for use in the treatment of symptoms of viral lung diseases including COVID-19 caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) by means of dry powder inhaler through inhalation. The present invention also relates to methods for preparation of said pharmaceutical composition and the use of these active substances in symptoms caused by COVID-19. similar viral lung diseases, influenza.

The present disclosure relates to physical forms of a DHODH inhibitor, such as a stable crystalline form of and compositions comprising the same. Also provided is the use of the physical form (such as a polymorph) or composition thereof in treatment, such as the treatment of a viral disease or an autoimmune disease or disorder.

The invention discloses a tomato disease-resistant gene mutant and application thereof in prevention and treatment of ToBRFV, and belongs to the technical field of biological prevention and treatment of viral diseases. According to the invention, the 1927th nucleotide of the coding region sequence of the tomato Tm-22 gene is mutated from G to A; or the 643th amino acid of the LRR structural domain of the tomato Tm-22 gene encoding protein is mutated from glycine to arginine, so that the accumulation level of ToBRFV capsid protein (CP) can be obviously reduced. The gene (named as Tm-22-Mut5) not only can be used as a new ToBRFV resistance gene, but also retains the resistance to TMV, ToMV and ToMMV. The method comprises the following steps: carrying out combined mutation on Tm-22-Mut5 and a Tm-22-Mut3-1 mutant (tyrosine at the 767th site in an LRR structural domain is mutated into phenylalanine) screened in an earlier stage, so as to obtain a mutant Tm-22-Mut6. According to the present invention, the analysis results show that the accumulation level of the ToBRFV capsid protein can be significantly reduced by using the Tm-22-Mut6; compared with a mutant pFGCTm-22-Mut3-1 obtained through early research and screening and a newly obtained mutant Tm-22-Mut5, the resistance of the Tm-22-Mut6 to the ToBRFV is further improved, and the resistance of the Tm-22-Mut6 to the ToBRFV is further improved.

Provided herein are antibodies and functional fragments thereof for the treatment or prophylaxis of viral diseases, such as poxvirus diseases, such as Chenpox and monkey pox. Any antibody or functional fragment thereof described herein may be an engineered antibody or an engineered antibody fragment. In addition, provided herein are compositions and pharmaceutical compositions containing one or more antibodies or functional fragments thereof. Also provided herein are kits containing one or more antibodies or functional fragments thereof, as well as methods, dosing regimens, dosage amounts, and pathways for administering one or more antibodies and one or more functional fragments thereof. Finally, methods of making the antibodies and functional fragments thereof are provided.

Provided are a fusion protein comprising recombinant porcine interferon λ1 and a use thereof, and a preparation method and use for the fusion protein. The fusion protein is formed by respectively linking porcine interferon λ1 to other fragments (such as porcine interferon γ) and / or porcine serum albumin (PSA) directly or indirectly by means of linker elements. The porcine interferon λ1 fusion protein can be prepared by using a mammalian cell expression system on the basis of genetic engineering technology. Compared with natural porcine interferon λ1, the provided recombinant porcine interferon λ1 fusion protein has a long half-life period and can be used for preparing drugs for preventing or treating porcine viral diseases.

The invention discloses an NDRV [sigma] C circular RNA vaccine and application thereof, and belongs to the technical field of vaccines.Duck hepatitis A virus type 1 (DHAV-1) UTR and T4 bacteriophage I type intron self-splicing cyclization systems are adopted to construct circular RNA (CirRNA-[sigma] C) for expressing NDRV [sigma] C protein, and a vaccine preparation is prepared through a chitosan-polyethyleneimine (CS-PEI) nano delivery system. The feasibility of a circular RNA vaccine system based on DHAV-1UTR in poultry vaccines is confirmed for the first time, the established nano delivery technology and circular RNA vaccine platform have the characteristics of high stability, good safety, strong immunogenicity and the like, and an important technical path is provided for development of novel vaccines of NDRV and other viral epidemic diseases.

The invention discloses a plant endogenous small molecule polypeptide and application thereof in inhibiting RNA virus infected plants, the sequence of the small molecule polypeptide is Pep1-3: IIGVSNFDPVKRS, and the small molecule polypeptide is derived from nicotiana benthamiana; the invention relates to application of plant endogenous small molecule polypeptide in inhibiting RNA virus infection of plants. The plant is tobacco; the RNA viruses comprise tobacco mosaic viruses, tomato mosaic viruses and turnip mosaic viruses, and the small peptide Pep1-3 serves as a novel plant immunity inducer and shows the potential of the small peptide Pep1-3 in the aspect of preventing and controlling the RNA viruses. In agricultural production, prevention and treatment of virus diseases by adopting oligopeptide substances are a green and sustainable direction, and compared with traditional pesticides and plant immunity inducers, the composition has the advantages of broad spectrum, small toxicity, no drug resistance risk and long lasting period, and can generate a synergistic or synergistic effect when being mixed with other medicaments.

A biocontrol agent of the present invention, comprising one or more of the selected, isolated bacteria disclosed herein, is useful in methods of protecting plants against disease or damage by plant pathogens. A method comprises applying a biocontrol agent to plants, plant seeds, or media or soil surrounding plants provide disease protection to plants or plants produced from the contacted plant seeds. Biocontrol agents of the present invention are useful in horticulture, aquaculture, aeroculture, hydroponic culture, agriculture and all types of plant growing conditions to protect plants from a variety of plant bacterial, fungal, and viral diseases. The compositions and methods of the present invention are effective against plant pathogens.

The present disclosure provides compounds of Formula I-V that are useful for inhibiting a viral disease in a subject. In some embodiments, the compounds of Formula I-V may be used to inhibit herpes virus.

The invention discloses a rice virus multiplex RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection kit, a detection system and application. In particular discloses a composition for simultaneously detecting three rice viruses RRSV, SRBSDV and RSMV, the composition comprises three primer pairs, and the nucleotide sequences of the three primer pairs are shown as SEQ ID NO: 1-SEQ ID NO: 6. The invention also discloses a multiplex RT-PCR detection method for simultaneously detecting the three rice viruses. The primer and the detection method thereof are sensitive, specific and good in stability, an efficient tool can be provided for early diagnosis of rice virus diseases, pathogen composition of field diseases can be rapidly and clearly determined by simultaneously detecting the three viruses, and precious time is gained for formulating targeted prevention and control measures. The method is easy and convenient to operate, can be completed only through conventional PCR equipment, is suitable for being popularized in primary laboratories and is beneficial to improving the virus monitoring capacity of main rice producing areas in China.

The present invention discloses an antibody-drug conjugate and a preparation method and application thereof, in particular, a conjugate of an anti-PD-L1 antibody and a TLR7 and / or TLR8 agonist and a pharmaceutical composition, preparation method and application thereof. The present invention obtains a modified anti-PD-L1 antibody with a mutant cysteine ​​by gene editing, which basically retains the structure of the original antibody and can be used for the construction of an antibody-drug conjugate. Through anti-tumor experiments, it was found that the obtained antibody-drug conjugate has better activity, such as strong anti-tumor activity, can significantly improve the survival rate of tumor-bearing animals, and has significantly reduced toxicity, less burden on the body of experimental animals, greatly reduces the minimum effective dose of small molecule drugs when used alone, expands its therapeutic window, and is expected to be used in the development of therapeutic drugs for various diseases (such as tumors, viral diseases such as hepatitis B, etc.), with good application prospects and value.

The invention belongs to the technical field of virus detection, and particularly relates to an anguilla positive reovirus (Anguilla positive reovirus) AORV-1025 as well as a primer group, a kit and a method for detecting the anguilla positive reovirus. According to the invention, a conserved sequence of an RdRp gene coded by an L3 segment of an eel positive reovirus genome is taken as a target, a primer group consisting of a primer pair and a probe is designed, and the primer group is used for detecting several different positive reoviruses including the eel positive reovirus and viruses possibly existing in a detection sample. The detection result is high in sensitivity, strong in specificity and excellent in repeatability, the eel positive reovirus in a sample can be rapidly and accurately detected in a fluorescent quantitative mode, the method is applied to research on eel positive reovirus infection, and the method has important significance on pathogen monitoring, differential diagnosis and guide prevention and control of eel viral diseases.

A fusion protein comprising an anti-PD1 antibody moiety having a C-terminus, and an IL21 mutant protein conjugated to the anti-PD1 antibody moiety having a C-terminus wherein the IL21 mutant protein comprises at least one of two mutations relative to wild-type IL21: (1) one of a K72Y substitution, a K72M substitution and a K72Q substitution, and (2) a 75-80 deletion. In some examples, the anti-PD1 antibody may take the ETYY format and may comprise: a first heavy chain comprising a VH comprising the sequence of SEQ ID NO: 11; and a second heavy chain comprising a VH comprising a sequence selected from the sequences of SEQ ID NO: 8-10. Also provided are pharmaceutical compositions comprising the fusion protein, nucleic acids encoding the fusion protein, vectors comprising the nucleic acids, and methods of administering the fusion protein to treat diseases.

The invention relates to the technical field of traditional Chinese veterinary medicines, in particular to a veterinary antiviral traditional Chinese medicine composition and a preparation method thereof.The traditional Chinese medicine composition is prepared from, by weight, 20-40 parts of gypsum and 15-30 parts of rhizoma anemarrhenae; 15-30 parts of cornu bubali; 10-15 parts of manyleaf paris rhizome; 10-15 parts of radix paeoniae rubra; 10 to 15 parts of moutan bark; 10 to 15 parts of uncaria rhynchophylla; 0.3-1 part of calculus bovis factitius; 15 to 30 parts of magnet; 1-3 parts of benzoin; 10-15 parts of radix trichosanthis; and 10-15 parts of cape jasmine. The preparation method comprises the following steps: decocting the traditional Chinese medicines to prepare traditional Chinese medicine decoction, and concentrating overnight filtrate under reduced pressure to obtain traditional Chinese medicine fluid extract; and adding clinically acceptable auxiliary materials into the traditional Chinese medicine fluid extract, and preparing a clinically acceptable oral traditional Chinese medicine preparation by adopting a conventional preparation mode. The veterinary antiviral traditional Chinese medicine composition provided by the invention has a good treatment effect on viral diseases of livestock according to the principle of dialectical treatment of traditional Chinese veterinary medicines, can be used for replacing western medicines, and effectively avoids the problems of food safety and drug resistance caused by drug residues of the western medicines.

The invention provides an oligopeptide with a fish virus resisting effect, and the oligopeptide is used as a feed additive or a liquid protein preparation for injection to kill viruses or inhibit the proliferation of the viruses, so that the treatment of the fish virus diseases is realized. The amino acid sequence of the oligopeptide is SEQ ID NO: 1. The Pt5-1c oligopeptide provided by the invention reduces the cytopathic effect degree of GCRV virus infection on EPC, and shows that the Pt5-1c oligopeptide has an important antiviral effect. By adding the Pt5-1c oligopeptide into the feed or injecting the Pt5-1c oligopeptide into the fish, the purpose of preventing and treating viral diseases of the fish can be achieved.

The present invention relates to a highly effective, broad-spectrum anti-plant viral disease pharmaceutical composition and its application. The active ingredients of the anti-plant viral disease pharmaceutical composition include chlorin iron and lentinan; wherein the weight ratio of chlorin iron to lentinan is 1:6000 to 4:1. When a certain concentration of the chlorin iron and lentinan pharmaceutical composition is applied to plants, the two active ingredients exert a synergistic effect, alleviating symptoms of diseased plants, reducing disease indexes, and reducing viral accumulation in the plants. The plant anti-viral disease pharmaceutical composition is a biological agent that is environmentally friendly, safe, and environmentally friendly. It has important application prospects in combating plant viral diseases, preventing and controlling plant diseases caused by plant viruses, and improving plant quality.

The invention relates to the technical field of botanical pesticides, and discloses a cistanche polysaccharide anti-plant virus agent as well as a preparation method and application thereof. The preparation is prepared into an aqueous solution by taking cistanche polysaccharide as an effective component and adding an auxiliary agent, and specifically comprises the following components in percentage by weight: 10-40% of a cistanche polysaccharide extract, 0-10% of an organic solvent, 1-20% of a surfactant, 1-5% of an anti-freezing agent, 1-5% of a preservative and the balance of water, and the sum of the weight percentages of the raw materials is 100%. The desertliving cistanche polysaccharide antiviral agent can be used for preventing and treating virus diseases such as ToBRFV and TMV on crops such as tomatoes, tobaccos and peppers, and healthy growth of the crops is guaranteed. The antiviral agent provided by the invention has the advantages of good effect, no drug resistance risk, no residual risk, high safety to non-target organisms, and ecological friendliness, and has the application prospect of industrially preparing green plant protection products.

A method of treating or decreasing the risk of developing a respiratory viral infection in a subject is described. The method includes administering a therapeutically effective amount of neuregulin to the subject. A method of decreasing the risk that a subject will develop post-viral airway disease by administering an effective amount of neuregulin to the subject is also described.

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1 / PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound as described herein, or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound as described herein, or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including, but not limited to, liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

The present invention relates to triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ringare as defined herein. The invention also relates to triterpene derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

This application relates to pyrimidine derivatives described in formula (I-1), formula (I-2), formula (II-1), or formula (II-2), or their stereoisomers, tautomers, isotopic derivatives, hydrates, solvates, prodrugs, and pharmaceutically acceptable salts, which can be used as effective TLR7 and / or TLR8 receptor agonists and are characterized by good selectivity, high activity, and excellent safety. This application also provides a method for preparing the pyrimidine derivatives and a pharmaceutical composition thereof. The compounds of this application or their pharmaceutical compositions can be used in the preparation of pharmaceuticals for the prevention or treatment of infectious diseases, respiratory diseases, immune-related diseases, viral diseases, or tumors. TIFF2026528992000173.tif3891

The present application discloses a method for preventing and treating flue-cured tobacco virus disease, belonging to the field of plant protection. The method comprises (1) prevention: applying agents during the seedling stage, before transplanting, after transplanting, and during the field stage of tobacco growth; during the seedling stage: applying guanidine-copper acetate before thinning, replanting, and weeding; applying amino oligosaccharides and antiviral microbial agents before sealing the trays; applying cinclostrobin acetate solution after sealing the trays and before cutting the leaves; applying ningnanmycin and amino oligosaccharides before and after transplanting; applying insecticides mixed with plant resistance inducers, antiviral microbial agents, trace elements, and foliar fertilizers from one week after transplanting the seedlings to the stage of clustering; (2) treatment of the disease. The method prevents flue-cured tobacco virus disease by applying antiviral agents early in the whole growth stage of tobacco; and combining the antiviral agents with other specific agents to improve tobacco plant resistance, reduce the incidence of viral diseases, and improve the cure rate of viral diseases.